Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 391

1.

Targeting ROR1 inhibits epithelial-mesenchymal transition and metastasis.

Cui B, Zhang S, Chen L, Yu J, Widhopf GF 2nd, Fecteau JF, Rassenti LZ, Kipps TJ.

Cancer Res. 2013 Jun 15;73(12):3649-60. doi: 10.1158/0008-5472.CAN-12-3832.

2.

Ovarian cancer stem cells express ROR1, which can be targeted for anti-cancer-stem-cell therapy.

Zhang S, Cui B, Lai H, Liu G, Ghia EM, Widhopf GF 2nd, Zhang Z, Wu CC, Chen L, Wu R, Schwab R, Carson DA, Kipps TJ.

Proc Natl Acad Sci U S A. 2014 Dec 2;111(48):17266-71. doi: 10.1073/pnas.1419599111. Epub 2014 Nov 19.

3.

Benzyl isothiocyanate inhibits epithelial-mesenchymal transition in cultured and xenografted human breast cancer cells.

Sehrawat A, Singh SV.

Cancer Prev Res (Phila). 2011 Jul;4(7):1107-17. doi: 10.1158/1940-6207.CAPR-10-0306. Epub 2011 Apr 4.

4.

ERbeta1 represses basal breast cancer epithelial to mesenchymal transition by destabilizing EGFR.

Thomas C, Rajapaksa G, Nikolos F, Hao R, Katchy A, McCollum CW, Bondesson M, Quinlan P, Thompson A, Krishnamurthy S, Esteva FJ, Gustafsson JÅ.

Breast Cancer Res. 2012 Nov 16;14(6):R148. doi: 10.1186/bcr3358.

5.

Fibroblast growth factor receptor splice variants are stable markers of oncogenic transforming growth factor β1 signaling in metastatic breast cancers.

Wendt MK, Taylor MA, Schiemann BJ, Sossey-Alaoui K, Schiemann WP.

Breast Cancer Res. 2014 Mar 11;16(2):R24. doi: 10.1186/bcr3623.

6.

ITF2 is a target of CXCR4 in MDA-MB-231 breast cancer cells and is associated with reduced survival in estrogen receptor-negative breast cancer.

Appaiah H, Bhat-Nakshatri P, Mehta R, Thorat M, Badve S, Nakshatri H.

Cancer Biol Ther. 2010 Sep 15;10(6):600-14. Epub 2010 Sep 4.

7.

ROR1 is expressed in human breast cancer and associated with enhanced tumor-cell growth.

Zhang S, Chen L, Cui B, Chuang HY, Yu J, Wang-Rodriguez J, Tang L, Chen G, Basak GW, Kipps TJ.

PLoS One. 2012;7(3):e31127. doi: 10.1371/journal.pone.0031127. Epub 2012 Mar 5.

8.

Histone deacetylase inhibitor entinostat reverses epithelial to mesenchymal transition of breast cancer cells by reversing the repression of E-cadherin.

Shah P, Gau Y, Sabnis G.

Breast Cancer Res Treat. 2014 Jan;143(1):99-111. doi: 10.1007/s10549-013-2784-7. Epub 2013 Dec 5.

PMID:
24305977
9.

Vascular endothelial growth factor receptor-1 activation promotes migration and invasion of breast cancer cells through epithelial-mesenchymal transition.

Ning Q, Liu C, Hou L, Meng M, Zhang X, Luo M, Shao S, Zuo X, Zhao X.

PLoS One. 2013 Jun 11;8(6):e65217. doi: 10.1371/journal.pone.0065217. Print 2013.

10.

The monoamine oxidase-A inhibitor clorgyline promotes a mesenchymal-to-epithelial transition in the MDA-MB-231 breast cancer cell line.

Satram-Maharaj T, Nyarko JN, Kuski K, Fehr K, Pennington PR, Truitt L, Freywald A, Lukong KE, Anderson DH, Mousseau DD.

Cell Signal. 2014 Dec;26(12):2621-32. doi: 10.1016/j.cellsig.2014.08.005. Epub 2014 Aug 22.

PMID:
25152370
11.

Activation of NF-κB by the RANKL/RANK system up-regulates snail and twist expressions and induces epithelial-to-mesenchymal transition in mammary tumor cell lines.

Tsubaki M, Komai M, Fujimoto S, Itoh T, Imano M, Sakamoto K, Shimaoka H, Takeda T, Ogawa N, Mashimo K, Fujiwara D, Mukai J, Sakaguchi K, Satou T, Nishida S.

J Exp Clin Cancer Res. 2013 Sep 5;32:62. doi: 10.1186/1756-9966-32-62.

12.

Fucoidan induces changes in the epithelial to mesenchymal transition and decreases metastasis by enhancing ubiquitin-dependent TGFβ receptor degradation in breast cancer.

Hsu HY, Lin TY, Hwang PA, Tseng LM, Chen RH, Tsao SM, Hsu J.

Carcinogenesis. 2013 Apr;34(4):874-84. doi: 10.1093/carcin/bgs396. Epub 2012 Dec 28.

13.

Suppression of FOXQ1 in benzyl isothiocyanate-mediated inhibition of epithelial-mesenchymal transition in human breast cancer cells.

Sehrawat A, Kim SH, Vogt A, Singh SV.

Carcinogenesis. 2013 Apr;34(4):864-73. doi: 10.1093/carcin/bgs397. Epub 2012 Dec 30.

14.

53BP1 suppresses epithelial-mesenchymal transition by downregulating ZEB1 through microRNA-200b/429 in breast cancer.

Kong X, Ding X, Li X, Gao S, Yang Q.

Cancer Sci. 2015 Aug;106(8):982-9. doi: 10.1111/cas.12699. Epub 2015 Jul 14.

15.

MicroRNA-7 inhibits epithelial-to-mesenchymal transition and metastasis of breast cancer cells via targeting FAK expression.

Kong X, Li G, Yuan Y, He Y, Wu X, Zhang W, Wu Z, Chen T, Wu W, Lobie PE, Zhu T.

PLoS One. 2012;7(8):e41523. doi: 10.1371/journal.pone.0041523. Epub 2012 Aug 2.

16.

Gemifloxacin inhibits migration and invasion and induces mesenchymal-epithelial transition in human breast adenocarcinoma cells.

Chen TC, Hsu YL, Tsai YC, Chang YW, Kuo PL, Chen YH.

J Mol Med (Berl). 2014 Jan;92(1):53-64. doi: 10.1007/s00109-013-1083-4. Epub 2013 Sep 5.

PMID:
24005829
17.

Re-expression of miR-21 contributes to migration and invasion by inducing epithelial-mesenchymal transition consistent with cancer stem cell characteristics in MCF-7 cells.

Han M, Liu M, Wang Y, Mo Z, Bi X, Liu Z, Fan Y, Chen X, Wu C.

Mol Cell Biochem. 2012 Apr;363(1-2):427-36. doi: 10.1007/s11010-011-1195-5. Epub 2011 Dec 21.

PMID:
22187223
18.

MiR-155-mediated loss of C/EBPβ shifts the TGF-β response from growth inhibition to epithelial-mesenchymal transition, invasion and metastasis in breast cancer.

Johansson J, Berg T, Kurzejamska E, Pang MF, Tabor V, Jansson M, Roswall P, Pietras K, Sund M, Religa P, Fuxe J.

Oncogene. 2013 Dec 12;32(50):5614-24. doi: 10.1038/onc.2013.322. Epub 2013 Aug 19.

19.

GATA3 inhibits breast cancer metastasis through the reversal of epithelial-mesenchymal transition.

Yan W, Cao QJ, Arenas RB, Bentley B, Shao R.

J Biol Chem. 2010 Apr 30;285(18):14042-51. doi: 10.1074/jbc.M110.105262. Epub 2010 Feb 26.

20.

Bmi-1 promotes invasion and metastasis, and its elevated expression is correlated with an advanced stage of breast cancer.

Guo BH, Feng Y, Zhang R, Xu LH, Li MZ, Kung HF, Song LB, Zeng MS.

Mol Cancer. 2011 Jan 28;10(1):10. doi: 10.1186/1476-4598-10-10.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk